Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

352 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cabozantinib for the treatment of solid tumors: a systematic review.
Maroto P, Porta C, Capdevila J, Apolo AB, Viteri S, Rodriguez-Antona C, Martin L, Castellano D. Maroto P, et al. Among authors: castellano d. Ther Adv Med Oncol. 2022 Jul 13;14:17588359221107112. doi: 10.1177/17588359221107112. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35847482 Free PMC article. Review.
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A; RECORD-1 Study Group. Motzer RJ, et al. Lancet. 2008 Aug 9;372(9637):449-56. doi: 10.1016/S0140-6736(08)61039-9. Epub 2008 Jul 22. Lancet. 2008. PMID: 18653228 Clinical Trial.
Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE).
Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, Díaz-Pérez JA, Martínez Del Prado MP, Alonso Orduña V, Sevilla-García I, Villabona-Artero C, Beguiristain-Gómez A, Llanos-Muñoz M, Marazuela M, Alvarez-Escola C, Castellano D, Vilar E, Jiménez-Fonseca P, Teulé A, Sastre-Valera J, Benavent-Viñuelas M, Monleon A, Salazar R. Garcia-Carbonero R, et al. Among authors: castellano d. Ann Oncol. 2010 Sep;21(9):1794-1803. doi: 10.1093/annonc/mdq022. Epub 2010 Feb 5. Ann Oncol. 2010. PMID: 20139156 Free article. Review.
Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity.
Bellmunt J, González-Larriba JL, Prior C, Maroto P, Carles J, Castellano D, Mellado B, Gallardo E, Perez-Gracia JL, Aguilar G, Villanueva X, Albanell J, Calvo A. Bellmunt J, et al. Among authors: castellano d. Ann Oncol. 2011 Dec;22(12):2646-2653. doi: 10.1093/annonc/mdr023. Epub 2011 Mar 21. Ann Oncol. 2011. PMID: 21427062 Free article. Clinical Trial.
Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study.
Garcia-Donas J, Esteban E, Leandro-García LJ, Castellano DE, González del Alba A, Climent MA, Arranz JA, Gallardo E, Puente J, Bellmunt J, Mellado B, Martínez E, Moreno F, Font A, Robledo M, Rodríguez-Antona C. Garcia-Donas J, et al. Lancet Oncol. 2011 Nov;12(12):1143-50. doi: 10.1016/S1470-2045(11)70266-2. Epub 2011 Oct 17. Lancet Oncol. 2011. PMID: 22015057
352 results